These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34699032)

  • 1. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
    Ren X; Yan C; Tian L; Cui X
    Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.
    Hua M; Xiong F; Chong S; Zhang Z; Liu Q; Hou J; Zhang Z; Gu Z; Cui X; Cui Y; Xu L; Xiang Q
    Cancer Treat Rev; 2024 Nov; 130():102827. PubMed ID: 39278067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
    Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
    Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
    Yan Y; Wu B; Wang L
    Expert Opin Drug Saf; 2024 Sep; 23(9):1191-1198. PubMed ID: 38482864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.
    Chen J; Tang L; Song W; Sun C; Zhang W
    Front Pharmacol; 2024; 15():1371346. PubMed ID: 39011505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS).
    Peng Y; Zhou Y; Zhou X; Jia X; Zhong Y
    Expert Opin Drug Saf; 2024 Aug; ():1-9. PubMed ID: 39083396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
    Go M; Noguchi Y; Masuda R; Asano H; Kimura M; Usami E; Yoshimura T
    Int J Cancer; 2024 Sep; 155(5):849-853. PubMed ID: 38619193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.